Illumina Dropped List Prices and Cut Discounts for Infinium Whole-Genome Kits After Affy's Price Cut | GenomeWeb
Illumina CEO Jay Flatley said the company last month dropped the list prices and reduced the discounts for its Infinium whole-genome genotyping kits a few weeks after rival Affymetrix cut the price of its 500K array kit.
Flatley’s remarks, made during a break-out session at the UBS Life Sciences Conference in New York last week, also come a little more than two months after he had said the company “feel[s] very comfortable with the position of our products in the market and the pricing of those products.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.